Mucosal healing

When the gut lining looks healed on a camera test, not just when symptoms have settled. Many IBD teams now aim for this as a treatment goal.

Also called: histological healing, healed lining, healing of the bowel lining, mucosa healing, gut lining healed, healed bowel lining

Related words treat to target remission mucosa endoscopic remission deep remission transmural healing

Topics Monitoring Research

Questions people ask

What does 'treat to target' mean?

It means your team agrees goals in advance and adjusts treatment until you reach them, rather than waiting for symptoms. The STRIDE-II expert agreement says early goals are feeling better and getting blood and poo inflammation tests back to normal; longer-term goals are a healed bowel lining, no disability, good quality of life and normal growth in children. The CALM trial found that stepping up treatment when tests showed inflammation, not just when symptoms flared, led to more bowel healing.

Sources

Why do I still need tests when I feel well?

Symptoms do not always match what is happening inside. Crohn's & Colitis UK says calprotectin can be raised even without symptoms, and tests check for anaemia and medicine side effects. Some teams use a 'treat to target' approach, aiming for healing of the gut lining and normal markers rather than just fewer symptoms. Monitoring may include blood and poo tests, scans, colonoscopy and, in some hospitals, home calprotectin kits.

Sources

Where to read more

Outcomes and Strategies to Support a Treat-to-target Approach in Inflammatory Bowel Disease: A Systematic Review

Journal of Crohn's and Colitis via PubMed Central Systematic review Feb 2020 For professionals

Reviews the evidence for 'treat to target', where treatment is adjusted not just to symptoms but to measured goals such as a healed bowel lining and normal blood or poo markers. It explains the idea behind the STRIDE targets and notes that firm proof that aiming for healing improves long-term outcomes was still emerging.

Topics Monitoring Research

Jargon explained treat to target mucosal healing biomarker STRIDE

Infliximab, azathioprine, or combination therapy for Crohn's disease (SONIC)

New England Journal of Medicine Study Apr 2010 Patients and professionals

A landmark trial of 508 adults with moderate to severe Crohn's who had never had immunosuppressants or biologics. Infliximab and azathioprine together worked best: about 57% were in remission without steroids at 26 weeks, against 44% on infliximab alone and 30% on azathioprine alone. This is why many people starting infliximab are offered a second 'helper' drug alongside it.

Topics Biologics and newer medicines Immunosuppressants Research

Jargon explained combination therapy steroid-free remission mucosal healing randomised controlled trial

Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial

The Lancet Study Dec 2017 Patients and professionals

CALM compared deciding treatment on symptoms alone with 'tight control', where treatment was stepped up if blood or poo tests (CRP and faecal calprotectin) showed inflammation even when people felt fine. After 48 weeks, 46% in the tight control group had a healed bowel lining compared with 30% in the symptom-only group. It is a cornerstone of the 'treat to target' approach.

Topics Monitoring Biologics and newer medicines Research

Jargon explained tight control faecal calprotectin CRP mucosal healing treat to target

STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD)

Gastroenterology Guideline Apr 2021 For professionals

An international expert agreement on what 'treat to target' should aim for in IBD. Short-term goals are feeling better and getting blood and poo inflammation tests back to normal. Long-term goals include a healed bowel lining seen at endoscopy, no disability, a normal quality of life, and normal growth in children. Healing through the full bowel wall in Crohn's is not yet a formal target but is a sign of deeper remission.

Topics Monitoring Research Medicines

Jargon explained treat to target endoscopic healing transmural healing biomarker calprotectin CRP clinical remission

Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease (SEQUENCE)

New England Journal of Medicine Study Jul 2024 Patients and professionals

A head-to-head trial in people whose Crohn's had not responded to, or who could not tolerate, anti-TNF drugs. Risankizumab (Skyrizi) was at least as good as ustekinumab (Stelara) for remission at 24 weeks and better at healing the bowel lining by 48 weeks. Side effects looked similar.

Topics Biologics and newer medicines Research

Jargon explained non-inferiority endoscopic remission anti-TNF

The Crohn's disease exclusion diet for induction and maintenance of remission in adults with mild-to-moderate Crohn's disease (CDED-AD)

The Lancet Gastroenterology & Hepatology Study Jan 2022 Patients and professionals

A small pilot trial of 44 adults with mild to moderate Crohn's who had not had biologics. The CDED, with or without supplement drinks, put more than half into remission at 6 weeks, and most of them were still in remission at 24 weeks. About a third had a healed bowel lining. The authors say a bigger trial is needed before firm conclusions.

Topics Diet and nutrition

Jargon explained pilot study open-label endoscopic remission

Management of pediatric Crohn's disease: an ECCO-ESPGHAN guideline update

ECCO and ESPGHAN (J Crohns Colitis) Guideline Aug 2026 For professionals

The newest European guideline for children with Crohn's, agreed by 27 experts. Children at high risk of a difficult course should start an anti-TNF biologic first, with blood-level checks of the drug. For lower-risk children, a liquid-only diet (EEN) or the Crohn's Disease Exclusion Diet with partial liquid feeds are the preferred first treatments. Long-term goals include a healed bowel lining, normal growth and a good quality of life.

Topics Children and young people Diet and nutrition Biologics and newer medicines Monitoring

Jargon explained anti-TNF therapeutic drug monitoring exclusive enteral nutrition endoscopic remission

Risankizumab as maintenance therapy for moderately to severely active Crohn's disease (FORTIFY)

The Lancet Study May 2022 For professionals

The main international trial of risankizumab injections to keep Crohn's under control after a good response to drip treatment. More people who stayed on risankizumab remained in remission and had gut healing than those switched to placebo, and side effects were similar between groups.

Topics Biologics and newer medicines Research

Jargon explained IL-23 maintenance placebo endoscopic response

Search everything for "mucosal healing"